دورية أكاديمية
أعرض في EDS

Lycium barbarum glycopeptide targets PER2 to inhibit lipogenesis in glioblastoma by downregulating SREBP1c.

التفاصيل البيبلوغرافية
العنوان: Lycium barbarum glycopeptide targets PER2 to inhibit lipogenesis in glioblastoma by downregulating SREBP1c.
المؤلفون: Yao J; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Hui JW; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Chen YJ; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Luo DY; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Yan JS; Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Zhang YF; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Lan YX; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Yan XR; Ningxia Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, Autonomous Region, 750004, China., Wang ZH; Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China., Fan H; Ningxia Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, Autonomous Region, 750004, China. fangheng@nxmu.edu.cn., Xia HC; Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, P.R. China. xhechun@nyfy.com.cn.; Ningxia Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, Autonomous Region, 750004, China. xhechun@nyfy.com.cn.
المصدر: Cancer gene therapy [Cancer Gene Ther] 2023 Aug; Vol. 30 (8), pp. 1084-1093. Date of Electronic Publication: 2023 Apr 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5500 (Electronic) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: <2002->: London : Nature Publishing Group
Original Publication: Norwalk, CT : Appleton & Lange, c1994-
مواضيع طبية MeSH: Lycium*/chemistry , Lycium*/metabolism , Glioblastoma*/drug therapy , Glioblastoma*/genetics, Humans ; Glycopeptides/metabolism ; Lipogenesis ; Phosphatidylinositol 3-Kinases/metabolism ; Period Circadian Proteins/metabolism
مستخلص: Lycium barbarum polysaccharide (LBP) is a substance with various biological activities extracted from Lycium barbarum. LbGPs are peptidoglycans with a short peptide backbone and a complex, branched glycan moiety, which is further extracted and isolated from LBPs. Previous studies have shown that LbGP can inhibit cancer cell growth, but its specific mechanism is not completely clear. In this study, we found that LbGP could inhibit the proliferation of glioma cells and promote the expression of period 2 (PER2) through the PKA-CREB pathway. In addition, LbGP could inhibit the de novo synthesis of lipids by downregulating SREBP1c and its target genes, which depended on the expression of PER2. Moreover, PER2 negatively regulated the expression of SREBP1c via suppressing PI3K/AKT/mTOR pathway. In summary, LbGP may upregulate the expression of PER2 to reduce the expression of SREBP1c, inhibit lipid synthesis in glioblastoma, and inhibit glioblastoma cell proliferation. This study provides an alternative drug for the treatment of glioma and elucidates its potential mechanism.
(© 2023. The Author(s).)
التعليقات: Erratum in: Cancer Gene Ther. 2023 May 3;:. (PMID: 37138098)
References: Oncol Lett. 2018 Aug;16(2):1981-1990. (PMID: 30008892)
Proc Nutr Soc. 2016 Nov;75(4):440-450. (PMID: 27225642)
Cell. 2012 Mar 30;149(1):36-47. (PMID: 22464322)
Med Oncol. 2011 Mar;28(1):121-6. (PMID: 20066520)
Iran J Basic Med Sci. 2016 Sep;19(9):1024-1030. (PMID: 27803791)
Med Oncol. 2010 Sep;27(3):785-90. (PMID: 19669955)
Clin Cancer Res. 2016 Nov 1;22(21):5337-5348. (PMID: 27281560)
J Sci Food Agric. 2013 Jan 15;93(1):149-56. (PMID: 22696075)
Nat Rev Cancer. 2011 Feb;11(2):85-95. (PMID: 21258394)
Int J Biol Macromol. 2020 Apr 15;149:639-650. (PMID: 31991207)
J Am Nutr Assoc. 2022 Aug;41(6):618-626. (PMID: 34213407)
Neural Regen Res. 2021 Mar;16(3):543-549. (PMID: 32985485)
Rejuvenation Res. 2010 Feb;13(1):47-53. (PMID: 20230278)
Nat Med. 2018 Dec;24(12):1795-1803. (PMID: 30523327)
PLoS Genet. 2014 Mar 06;10(3):e1004155. (PMID: 24603613)
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419836494. (PMID: 30943793)
Stem Cells. 2013 Jan;31(1):146-55. (PMID: 23034897)
Nat Metab. 2022 Jun;4(6):711-723. (PMID: 35739397)
Oncol Rep. 2020 Aug;44(2):533-542. (PMID: 32468039)
Cell. 2006 Jan 13;124(1):35-46. (PMID: 16413480)
J Exp Med. 2021 Jan 4;218(1):. (PMID: 33601415)
J Cancer. 2020 Mar 26;11(12):3655-3666. (PMID: 32284762)
Cell. 2002 Oct 4;111(1):41-50. (PMID: 12372299)
Cancer Lett. 2014 Jan 1;342(1):9-18. (PMID: 24099911)
Int J Oncol. 2018 Jan;52(1):279-287. (PMID: 29115399)
Life Sci. 2005 Mar 18;76(18):2115-24. (PMID: 15826878)
المشرفين على المادة: 0 (Glycopeptides)
EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
0 (PER2 protein, human)
0 (Period Circadian Proteins)
تواريخ الأحداث: Date Created: 20230417 Date Completed: 20230816 Latest Revision: 20230826
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10425286
DOI: 10.1038/s41417-023-00611-4
PMID: 37069338
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5500
DOI:10.1038/s41417-023-00611-4